Cohance Lifesciences Limited — Investor Meet, 13-12-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Suven Pharmaceuticals reported a plan to acquire a 56% stake in NJ Bio, Inc. for an equity valuation of approximately $100 million, translating to a low to mid-teens EV/EBITDA. NJ Bio expects to achieve revenues of approximately $32 million in the year ending December 2024, reflecting a robust 70% CAGR over the last four years. Management anticipates that combined EBITDA margins will improve to over 20% post-integration.

2. Future Outlook and Growth Drivers: Management's strategic vision emphasizes becoming a leading CDMO in antibody-drug conjugates (ADCs). The acquisition is expected to enhance Suven’s capabilities in ADC development and expand its presence in the US, a key market for ADC innovation.

3. Order Book and Operational Updates: NJ Bio has partnered with over 150 clients and has successfully delivered more than 500 projects in the past five years. This established network provides a strong foundation for future growth, particularly as they enhance their GMP manufacturing capabilities.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts probed around revenue projections, with management emphasizing the significant growth potential post-acquisition.

- Market Position and Competitive Landscape: Discussions indicated that the combined entity aims to leverage its unique technology and capabilities to capture a larger share of the growing ADC market amidst rising competition.

- Operational Challenges or Risks: Management acknowledged ongoing investments in R&D and manufacturing while expressing confidence in overcoming capacity scaling challenges.

- Capex and Capital Allocation: A $15 million investment will focus on expanding NJ Bio's GMP capabilities, strategically positioning the company to meet increasing client demands.

- Strategic Priorities and Long-Term Vision: The integration seeks to provide a seamless end-to-end solution for ADC development, strengthening the company’s market position.

5. Market or Regulatory Updates: The acquisition is anticipated to close by the end of December, contingent on regulatory approvals, which could influence operational timelines and financial projections.

6. Strategic Focus Areas: Suven's management is committed to technological innovation and operational synergies, reinforcing its growth strategy within the ADC space and broader biopharma landscape.

7. Investor Insight: The acquisition aligns well with Suven's growth strategy, enhancing its technological edge. The financial outlook, increased market presence, and well-managed operational integration indicate a favorable investment stance moving forward.